Arcellx, Inc. (NASDAQ:ACLX) Shares Acquired by RA Capital Management L.P.

RA Capital Management L.P. grew its position in Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 50.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,787,327 shares of the company's stock after buying an additional 935,848 shares during the period. Arcellx makes up about 2.8% of RA Capital Management L.P.'s investment portfolio, making the stock its 9th largest holding. RA Capital Management L.P. owned about 5.15% of Arcellx worth $213,760,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of ACLX. Schonfeld Strategic Advisors LLC bought a new position in Arcellx in the 4th quarter worth approximately $2,511,000. Northern Trust Corp boosted its position in shares of Arcellx by 6.9% during the fourth quarter. Northern Trust Corp now owns 410,733 shares of the company's stock valued at $31,499,000 after buying an additional 26,625 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of Arcellx by 15.9% in the fourth quarter. The Manufacturers Life Insurance Company now owns 98,314 shares of the company's stock worth $7,540,000 after purchasing an additional 13,475 shares during the last quarter. Artia Global Partners LP bought a new stake in Arcellx during the 4th quarter valued at $17,622,000. Finally, Decheng Capital LLC grew its stake in Arcellx by 298.4% in the fourth quarter. Decheng Capital LLC now owns 84,377 shares of the company's stock valued at $6,471,000 after purchasing an additional 63,200 shares during the last quarter. Institutional investors own 96.03% of the company's stock.

Insider Activity at Arcellx

In other Arcellx news, insider Christopher Heery sold 10,155 shares of the company's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $63.79, for a total value of $647,787.45. Following the completion of the transaction, the insider now owns 37,486 shares in the company, valued at $2,391,231.94. This represents a 21.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Kavita Patel sold 1,500 shares of the stock in a transaction that occurred on Tuesday, April 8th. The shares were sold at an average price of $57.50, for a total value of $86,250.00. The disclosure for this sale can be found here. Insiders sold 54,455 shares of company stock worth $3,407,903 in the last three months. 6.24% of the stock is owned by company insiders.

Arcellx Price Performance

NASDAQ:ACLX traded down $10.53 during midday trading on Tuesday, hitting $54.12. The company's stock had a trading volume of 1,425,114 shares, compared to its average volume of 646,416. Arcellx, Inc. has a fifty-two week low of $47.88 and a fifty-two week high of $107.37. The firm's 50 day moving average is $64.99 and its 200-day moving average is $73.54. The firm has a market cap of $2.98 billion, a P/E ratio of -76.22 and a beta of 0.34.

Arcellx (NASDAQ:ACLX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.24). Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. The company had revenue of $15.27 million for the quarter, compared to analysts' expectations of $27.42 million. As a group, analysts forecast that Arcellx, Inc. will post -1.58 EPS for the current year.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).